XML 25 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:      
Total revenue $ 140,734 $ 235,309 $ 176,319
Operating costs and expenses:      
Cost of goods sold $ 20,280 $ 12,871 $ 8,869
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 296,791 $ 387,043 $ 252,924
Selling, general and administrative 124,688 123,925 106,406
Total operating costs and expenses 441,759 523,839 368,199
Loss from operations (301,025) (288,530) (191,880)
Interest and other, net      
Interest expense (1,440) (1,075) (2,402)
Interest income and other income (expenses), net 7,596 (1,078) 5,553
Total interest and other, net 6,156 (2,153) 3,151
Loss before income taxes (294,869) (290,683) (188,729)
Provision for income taxes 358 347 360
Investment income (loss) in unconsolidated variable interest entity 1,573 1,007 (202)
Net loss $ (293,654) $ (290,023) $ (189,291)
Net loss per share - basic $ (3.14) $ (3.14) $ (2.11)
Net loss per share - diluted $ (3.14) $ (3.14) $ (2.11)
Weighted average number of common shares used to calculate net income (loss) per share:      
Basic 93,582 92,349 89,854
Diluted 93,582 92,349 89,854
License Revenue [Member]      
Revenue:      
Total revenue $ 22,590 $ 116,434 $ 14,323
Development and Other Revenue [Member]      
Revenue:      
Total revenue 24,189 70,275 80,592
Product Revenue, Net [Member]      
Revenue:      
Total revenue 82,869 47,638 72,498
Drug Product Revenue [Member]      
Revenue:      
Total revenue $ 11,086 $ 962 $ 8,906